William R. Hiatt American cardiologist
Hiatt, William R.
Hiatt, W. R.
VIAF ID: 313526543 (Personal)
Permalink: http://viaf.org/viaf/313526543
Preferred Forms
-
- 100 1 _ ‡a Hiatt, William R.
-
-
- 100 1 _ ‡a Hiatt, William R.
- 100 0 _ ‡a William R. Hiatt ‡c American cardiologist
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease | |
Heterogeneity of Risk and Benefit in Subgroups of COMPASS: Relatively Similar But Absolutely Different | |
A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life | |
The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. | |
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model | |
Is revascularization and limb salvage always the best treatment for critical limb ischemia? | |
Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes | |
Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization | |
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). | |
Lost in translation: Why 'lost to follow-up' matters | |
Managing abnormal blood lipids: a collaborative approach | |
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE | |
Measurement characteristics of the ankle-brachial index: results from the Action for Health in Diabetes study | |
No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials | |
The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease | |
Optimal assessment of baseline treadmill walking performance in claudication clinical trials | |
Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association | |
Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia | |
The Pathobiology of Acute Limb Ischemic Events and Stent Failure in Peripheral Artery Disease: A Step in the Right Direction | |
Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial design. | |
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. | |
Peripheral arterial disease handbook, 2001: | |
Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial | |
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients | |
Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting | |
Proceedings from the Society of Interventional Radiology research consensus panel on critical limb ischemia | |
Prognostic value of an increase in post-exercise ankle-brachial index | |
Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back | |
Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials | |
Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy | |
Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells | |
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study | |
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study | |
Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs | |
Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease | |
Response by Hess and Hiatt to Letter Regarding Article, "A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) In | |
Response to McDermott | |
Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies | |
Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk | |
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety | |
Sharing Data from Cardiovascular Clinical Trials--A Proposal | |
The Society for Vascular Medicine: the first quarter century. | |
Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function | |
A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication | |
Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD | |
TASC II section F on revascularization in PAD. | |
Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution | |
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial | |
The treadmill is a better functional test than the 6-minute walk test in therapeutic trials of patients with peripheral artery disease | |
Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial | |
Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia | |
Use of ankle brachial index screening for selecting patients for antiplatelet drug therapy | |
Utility and barriers to performance of the ankle brachial index in primary care practice | |
What cost weight loss? | |
Why TASC II? | |
Wound healing and functional outcomes after infrainguinal bypass with reversed saphenous vein for critical limb ischemia | |
Wpływ atorwastatyny na dystans chromania przestankowego u chorych na chorobę tętnic obwodowych |